PAP
MPLT

Persistent Asset Partners’s MapLight Therapeutics MPLT Stock Holding History

Persistent Asset Partners’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-21,766
Closed -$382K – 508
2025
Q4 		$382K Buy
+21,766
New +$365K 0.17% 155

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Persistent Asset Partners's MPLT Position: Q1 2026 in Review

Persistent Asset Partners sold out of MapLight Therapeutics (MPLT) in Q1 2026, closing a stake of 21,766 shares — an estimated $382K sold.

Persistent Asset Partners first reported a position in MPLT in Q4 2025 and held it in 1 quarter. The position peaked at $382K in Q4 2025. 81 funds tracked by Wall St. Rank hold MPLT as of Q1 2026.

  • Persistent Asset Partners reported no remaining MapLight Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 21,766 MapLight Therapeutics shares in Q1 2026, an estimated $382K.
  • Persistent Asset Partners first reported a position in MapLight Therapeutics in Q4 2025 and held it in 1 quarter.
  • Persistent Asset Partners's MapLight Therapeutics position peaked at $382K in Q4 2025.
  • 81 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.